Patent · US Active

Interleukin-9 mutein peptides

US7700088B2 · kind B2 · utility

16Cited by

11References

16Claims

0Family size

Assignee

GENEIAL LLC · JP

Inventors

Roy Levitt · Ambler, US
W. Lee Maloy · Lansdale, US
U. Prasad Kari · Lansdale, US
Nicholas C. Nicolaides · Boothwyn, US

Key dates

Filing date	Mar 7, 2007
Grant date	Apr 20, 2010
Priority date	—
Expiry date	Mar 7, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.